Literature DB >> 28815607

A 3D tri-culture system reveals that activin receptor-like kinase 5 and connective tissue growth factor drive human glomerulosclerosis.

John P Waters1, Yvonne C Richards1, Jeremy N Skepper2, Mark Southwood3, Paul D Upton1, Nicholas W Morrell1, Jordan S Pober4, John R Bradley1.   

Abstract

Glomerular scarring, known as glomerulosclerosis, occurs in many chronic kidney diseases and involves interaction between glomerular endothelial cells (GECs), podocytes, and mesangial cells (MCs), leading to signals that promote extracellular matrix deposition and endothelial cell dysfunction and loss. We describe a 3D tri-culture system to model human glomerulosclerosis. In 3D monoculture, each cell type alters its phenotype in response to TGFβ, which has been implicated as an important mediator of glomerulosclerosis. GECs form a lumenized vascular network, which regresses in response to TGFβ. MCs respond to TGFβ by forming glomerulosclerotic-like nodules with matrix deposition. TGFβ treatment of podocytes does not alter cell morphology but increases connective tissue growth factor (CTGF) expression. BMP7 prevents TGFβ-induced GEC network regression, whereas TGFβ-induced MC nodule formation is prevented by SMAD3 siRNA knockdown or ALK5 inhibitors but not BMP7, and increased phospho-SMAD3 was observed in human glomerulosclerosis. In 3D tri-culture, GECs, podocytes, and MCs form a vascular network in which GECs and podocytes interact intimately within a matrix containing MCs. TGFβ treatment induces formation of nodules, but combined inhibition of ALK5 and CTGF is required to prevent TGFβ-induced nodule formation in tri-cellular cultures. Identification of therapeutic targets for glomerulosclerosis depends on the 3D culture of all three glomerular cells.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  TGFβ; endothelial; glomerulosclerosis; mesangial; podocyte

Mesh:

Substances:

Year:  2017        PMID: 28815607      PMCID: PMC6309868          DOI: 10.1002/path.4960

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

1.  Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus.

Authors:  M Iwano; A Kubo; T Nishino; H Sato; H Nishioka; Y Akai; H Kurioka; Y Fujii; M Kanauchi; H Shiiki; K Dohi
Journal:  Kidney Int       Date:  1996-04       Impact factor: 10.612

2.  Models of chronic kidney disease.

Authors:  Hai-Chun Yang; Yiqin Zuo; Agnes B Fogo
Journal:  Drug Discov Today Dis Models       Date:  2010

Review 3.  The mesangial cell revisited: no cell is an island.

Authors:  Detlef Schlöndorff; Bernhard Banas
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

4.  Heterozygous mice for TGF-betaIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy.

Authors:  Hwal Woong Kim; Bong Cho Kim; Chi Young Song; Ji Hoon Kim; Hye Kyoung Hong; Hyun Soon Lee
Journal:  Kidney Int       Date:  2004-11       Impact factor: 10.612

5.  Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease.

Authors:  J B Kopp; V M Factor; M Mozes; P Nagy; N Sanderson; E P Böttinger; P E Klotman; S S Thorgeirsson
Journal:  Lab Invest       Date:  1996-06       Impact factor: 5.662

6.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

Authors:  N Sanderson; V Factor; P Nagy; J Kopp; P Kondaiah; L Wakefield; A B Roberts; M B Sporn; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Expression of transforming growth factor-beta isoforms in human glomerular diseases.

Authors:  T Yamamoto; N A Noble; A H Cohen; C C Nast; A Hishida; L I Gold; W A Border
Journal:  Kidney Int       Date:  1996-02       Impact factor: 10.612

8.  Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney.

Authors:  Y Isaka; Y Fujiwara; N Ueda; Y Kaneda; T Kamada; E Imai
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts.

Authors:  F S Shihab; T Yamamoto; C C Nast; A H Cohen; N A Noble; L I Gold; W A Border
Journal:  J Am Soc Nephrol       Date:  1995-08       Impact factor: 10.121

10.  United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease.

Authors:  Allan J Collins; Robert N Foley; David T Gilbertson; Shu-Cheng Chen
Journal:  Kidney Int Suppl (2011)       Date:  2015-06
View more
  3 in total

Review 1.  Organs-on-chip technology: a tool to tackle genetic kidney diseases.

Authors:  Marta G Valverde; João Faria; Elena Sendino Garví; Manoe J Janssen; Rosalinde Masereeuw; Silvia M Mihăilă
Journal:  Pediatr Nephrol       Date:  2022-03-14       Impact factor: 3.651

Review 2.  Biomimetic models of the glomerulus.

Authors:  Marta G Valverde; Luis S Mille; Kianti P Figler; Ernesto Cervantes; Vanessa Y Li; Joseph V Bonventre; Rosalinde Masereeuw; Yu Shrike Zhang
Journal:  Nat Rev Nephrol       Date:  2022-01-21       Impact factor: 28.314

Review 3.  Glomerular Endothelial Cell Crosstalk With Podocytes in Diabetic Kidney Disease.

Authors:  Nassim Mahtal; Olivia Lenoir; Pierre-Louis Tharaux
Journal:  Front Med (Lausanne)       Date:  2021-03-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.